Ascenta Capital — 2024 Investments

3 investments dated 2024 · listed companies and verified rows first · show all

Alpha-9 Oncologya9oncology.com inOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)

Co-investorsAndreessen Horowitz Delos Capital Frazier Life Sciences General Catalyst Lightspeed Venture Partners Longitude Capital +8 more

Alpha-9 Theranostics Inc.alpha9tx.com inJan 2024

Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.

BiotechLongevityMedical DevicesBoston, US

Co-investorsFrazier Life Sciences WUTIF Capital Biotechnology Value Fund Lightspeed Venture Partners Longitude Capital Nextech Invest +1 more

Cardurion Pharmaceuticalscardurion.com inJul 2024 · $260M

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

Michael E. Mendelsohn(Founder and Chief Strategy Officer)in

Co-investorsBain Capital Delos Capital Digitalis Ventures New Enterprise Associates (NEA)Bain Capital Life Sciences Bain Capital Tech Opportunities +4 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.